Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D1.182 - Investigation of risk factors for the development of food-induced enterocolitis syndrome in children with a history of allergic proctocolitis caused by milk
D1.184 - Evaluation of recombinant GAPDH for validation as a new apple allergen in the Mexican pediatric population
D1.185 - One-day oral challenge test in low risk nut allergic children
D1.186 - Reggsolving the eggnigma. Characteristics and prognosis of egg FPIES in children
D1.187 - The role of gut microbiota in non-specific lipid transfer protein (nsLTP) allergies: insights from 16S rRNA gene sequencing
D1.188 - Diet Diversity in Early Childhood, and Prevalence of Food Allergies in Children with Autism Spectrum Disorder
D1.189 - An Analysis of Adrenaline Auto-Injector distribution in the Republic of Ireland between 2019 to 2023
D1.191 - Global Survey on Healthcare Provider Practices in the Primary Prevention of Food Allergy: Implementation and Regional Gaps
D1.192 - Natural Course and Predictors of Cow’s Milk Allergy Resolution in an Asian Pediatric Cohort: Data from a Tertiary Care Center
D1.193 - Pumpkin Seed Allergy in Children
D1.194 - Phylogenetic relationships across allergenic foods to guide the risk assessment of novel food proteins
D1.195 - Immunoproteomic study of pear (Pyrus communis) in mexican population
D1.196 - Characterizing the detectable milk protein allergens in milk ladder foods
D1.197 - Casual consumption of small amounts of peanut in children with IgE-mediated allergy is associated with outgrowing IgE-mediated peanut allergy: results of a retrospective observational study
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download